Leerink Partners downgraded Shockwave Medical (NASDAQ:SWAV) from "outperform" to "market perform" rating.
Leerink Partners downgraded Shockwave Medical (NASDAQ:SWAV) from an "outperform" to a "market perform" rating, with an average consensus rating of "Hold" and a consensus price target of $305.70. Shockwave Medical reported $1.16 earnings per share for Q1, exceeding the consensus estimate by $0.24 and a 41% revenue increase from the previous year. The company's shares opened at $325.60 with a $12.18 billion market capitalization.
April 09, 2024
4 Articles